How Has the Macular Degeneration Treatment Market Evolved Historically and What is its Current Size
The macular degeneration treatment market has seen considerable growth due to a variety of factors.
• There has been a significant upsurge in recent times in the market size of macular degeneration treatments. From being valued at $11.05 billion in 2024, it is projected to grow to $12.42 billion in 2025 with a compound annual growth rate (CAGR) of 12.4%.
The phenomenal growth during the historic phase can be credited to several factors including an aging population, alterations in lifestyle, lack of adequate treatment options, increased awareness, and improvement in healthcare infrastructure.
What Does Future Hold for The Macular Degeneration Treatment Market Size?
The macular degeneration treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market for macular degeneration treatment is projected to experience substantial expansion in the coming years, reaching $19.06 billion in 2029 with a compound annual growth rate (CAGR) of 11.3%.
The predicted growth during this timeframe is due to factors such as progress in scientific research, increased spending on healthcare, higher occurrence rates, personalized medical treatment methods, and worldwide actions aimed at improving vision health. Key trends during this period encompass concentration on neuroprotection and regenerative therapies, the growth of telemedicine and remote patient observation, customized medical treatment methods, research into stem cell therapies, and campaigns aimed at patient awareness and education.
What Key Factors and Trends are Driving the Growth of the Macular Degeneration Treatment Market?
The escalating prevalence of retinal disorders is anticipated to boost the expansion of the macular degeneration treatment market. These disorders impair the essential tissue and hamper the processing of visual data, resulting in skewed or non-existent vision. For example, the American Academy of Ophthalmology predicts that by 2050, around 7.32 million people in the United States will be afflicted with primary open-angle glaucoma, a broad classification that comprises several eye disorders. These afflictions are most commonplace in populations aged 70-79 years (32%), women (50%), and Hispanics (50%), with Hispanic men being the most significantly impacted demographic. Hence, the surging prevalence of retinal disorders is fueling the expansion of the macular degeneration treatment market.
What Is The Segmentation Of The Global Macular Degeneration Treatment Market?
The macular degeneration treatment market covered in this report is segmented –
1) By Stage of Disease: Early-Stage AMD, Intermediate AMD, Late-Stage AMD
2) By End User: Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals
3) By Route of Administration: Oral, Injectable, Other Route of Administration
4) By Types: Wet Macular Degeneration, Dry Macular Degeneration
Subsegments:
1) By Early-Stage AMD: Nutritional Supplements, Lifestyle Modification Treatments
2) By Intermediate AMD: Anti-VEGF Injections, Photodynamic Therapy
3) By Late-Stage AMD: Surgical Treatments, Advanced Anti-VEGF Therapies, Gene Therapy Options
Pre-Book The Macular Degeneration Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Shaping The Macular Degeneration Treatment Market Landscape?
In the realm of macular degeneration treatment, primary corporations are concentrating on the creation of biosimilars intended for age-related macular degeneration (AMD) treatment, with the goal of improving access to powerful therapies. Biosimilars are medicinal biological substances that equivalently resemble an already certified reference substance, exhibiting no critical variances with respect to safety, purity, or effectiveness. For example, in May 2024, Biocon Biologics Ltd, from India, and Samsung Bioepis Co. Ltd, from South Korea, secured FDA approvals for Yesafili and Opuviz. These two novel biosimilars obstruct vascular endothelial growth factor (VEGF), a molecule that triggers abnormal blood vessel growth in the eye. This strategy aids in averting vision impairment connected to diseases such as AMD and diabetic retinopathy. Yesafili and Opuviz were ascertained to have no significant variations in effectiveness or safety compared to Eylea through comparative studies included in the FDA's approval plan. These studies involved meticulous evaluation of pharmacokinetics and immunogenicity of the biosimilars.
Who Are the Key Players in the Macular Degeneration Treatment Market?
Major companies operating in the macular degeneration treatment market include:
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Allergan Inc.
• Bayer AG
• Novartis AG
• GlaxoSmithKline plc
• Panoptica
• Regeneron Pharmaceuticals Inc.
• Bausch Health Companies Inc.
• Santen Pharmaceuticals
• Aerie Pharmaceuticals Inc.
• BioXcel Therapeutics Inc.
• Regenxbio Inc.
• Spark Therapeutics Inc.
• Alimera Sciences Inc.
• Applied Genetic Technologies Corp (AGTC)
• Cell Medica Ltd.
• Ophthotech Corporation
• Adverum Biotechnologies Inc.
• Neurotech Pharmaceuticals Inc.
• 4D Molecular Therapeutics Inc.
• GenSight Biologics Inc.
What are the Regional Insights into the Macular Degeneration Treatment Market?
North America was the largest region in the macular degeneration treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment Market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
